Hospital Clinico Universitario Lozano Blesa

The oncology department at Hospital Clinico Universitario Lozano Blesa focuses on advancing treatment for a wide range of cancers, including breast cancer, non‑small cell lung cancer, and ovarian malignancies. Trials aim to test new targeted therapies, immunotherapy combinations, and novel maintenance strategies to improve survival and reduce recurrence.

• Advanced triple‑negative breast cancer
• HER2‑positive metastatic breast cancer
• Advanced or metastatic non‑small cell lung cancer
• High‑grade serous ovarian cancer
• Renal cell carcinoma
• Urothelial carcinoma

These studies seek to expand therapeutic options and personalize care for patients with aggressive or treatment‑resistant tumors.

Research at the site includes investigations into heart failure and coronary conditions, with an emphasis on evaluating novel pharmacologic agents such as angiotensin receptor‑neprilysin inhibitors for transthyretin amyloid cardiomyopathy.

• Acute heart failure
• Heart failure with preserved ejection fraction
• Spontaneous coronary artery dissection
• Cardiovascular complications of metabolic disease

The goal is to improve cardiac function, reduce hospitalizations, and extend quality‑adjusted life years for patients with serious heart conditions.

The department conducts trials targeting lung disorders, from chronic obstructive pulmonary disease to various forms of lung cancer. Studies assess the safety and efficacy of inhaled bronchodilators, as well as immunotherapy‑based regimens for malignant disease.

• Chronic obstructive pulmonary disease (COPD)
• Small‑cell lung cancer
• Non‑small cell lung cancer with KRAS G12C mutation
• Advanced squamous cell carcinoma of the lung

By integrating respiratory function outcomes with oncologic endpoints, these trials aim to enhance both symptom control and survival.

Investigations address autoimmune and inflammatory conditions, exploring biologic agents and small‑molecule inhibitors to modulate immune pathways. Trials include patients with inflammatory bowel disease and rare vasculitides.

• Moderately to severely active Crohn's disease
• Moderately to severely active ulcerative colitis
• Eosinophilic granulomatosis with polyangiitis (EGPA)
• Chronic lymphocytic leukemia (immune‑related aspects)

The research seeks to achieve durable remission while minimizing systemic side effects.

Clinical work focuses on gastrointestinal malignancies and functional disorders, evaluating new chemotherapeutic combinations and targeted agents for colorectal cancer and gastric adenocarcinoma, as well as supportive therapies for malabsorption.

• Metastatic colorectal cancer
• Gastric adenocarcinoma
• Intestinal malabsorption in preterm infants
• Inflammatory bowel disease (Crohn's, ulcerative colitis)

Outcomes aim to increase response rates, enable surgical resection, and improve nutritional status.

The ophthalmology research program evaluates innovative intravitreal therapies for retinal conditions, including treatments for diabetic macular edema and geographic atrophy associated with age‑related macular degeneration.

• Diabetic macular edema
• Geographic atrophy secondary to AMD
• Neovascular age‑related macular degeneration (wet AMD)

These studies aim to preserve visual acuity and reduce disease progression in patients at risk of vision loss.

Trials in this area address gynecologic oncology and reproductive health, testing novel agents for advanced ovarian, endometrial, and cervical cancers, as well as assessing adjuvant therapies to prevent recurrence.

• Advanced high‑grade serous ovarian cancer
• Advanced endometrial carcinoma
• Intermediate‑risk cervical cancer
• High‑risk HER2‑negative breast cancer with hormonal components

The objective is to improve disease‑free survival and offer fertility‑preserving options when feasible.